Rifamycin antibiotics

Mar 31, 2020

Bausch Health Announces Favorable Topline Results From Study Evaluating Investigative Formulation of Rifaximin SSD IR to Treat Overt Hepatic Encephalopathy

Oct 31, 2019

Salix Announces Issuance of an Additional XIFAXAN® Patent

Apr 25, 2019

Global $385 Mn Traveler's Diarrhea Markets, 2019-2028

Dec 12, 2018

Bausch Health Enters Into Definitive "Stalking Horse" Agreement To Acquire Substantially All The Assets Of Synergy Pharmaceuticals Inc.

Nov 16, 2018

FDA approves new drug to treat travelers' diarrhea

Oct 29, 2018

Salix And Alfasigma Will Initiate Late-Stage Program To Study Rifaximin In Patients With Postoperative Crohn's Disease

Oct 08, 2018

Salix to Present Clinical Data for XIFAXAN® (RIFAXIMIN) and PLENVU® at the American College of Gastroenterology Annual Meeting

Jun 03, 2018

Salix Presents Positive Phase 3 Investigational Study Data For Repeat Rifaximin Treatment In Patients With Diarrhea Predominant Irritable Bowel Syndrome

Jun 03, 2018

Salix Presents Rifaximin Phase 3 Study Results for Irritable Bowel Syndrome with Diarrhea at Digestive Disease Week

May 31, 2018

Salix To Highlight New Clinical Data During Digestive Disease Week